PMID- 27114254
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160610
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 7
IP  - 2
DP  - 2016 Jun
TI  - Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in 
      Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
PG  - 309-20
LID - 10.1007/s13300-016-0170-2 [doi]
AB  - INTRODUCTION: A 12-week prospective study was previously performed to assess the 
      effect of add-on therapy with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) 
      inhibitor, in patients with type 2 diabetes mellitus (T2DM) receiving insulin 
      treatment. Patients were followed until week 48 to investigate the medium-term 
      efficacy and safety of the add-on therapy with sitagliptin. METHODS: In the 70 
      patients with T2DM, glycemic control, insulin dosage, concomitant medications, 
      body weight, laboratory parameters, and adverse events were evaluated for 
      48 weeks. RESULTS: Hemoglobin A1c (HbA1c) improved significantly from 8.03% at 
      week 0 (at initiation of the add-on therapy) to 7.45% at week 48 (P < 0.01). Body 
      weight remained nearly the same. The daily insulin dose was significantly reduced 
      by 2.5 U, from 25.8 to 23.3 U/day (P < 0.001). Stratified analysis of the 
      improvement of HbA1c based on age, duration of diabetes, body mass index, insulin 
      regimen, and oral antidiabetic drugs did not identify any significant differences 
      in relation to these parameters. During the 48-week follow-up period, there were 
      no problematic adverse events, such as severe hypoglycemia, and the add-on 
      therapy with sitagliptin showed good tolerability. CONCLUSIONS: In Japanese 
      patients with T2DM receiving insulin treatment, add-on therapy with sitagliptin 
      was not associated with weight gain and allowed for the reduction of the insulin 
      dosage. Consistent efficacy was noted for 48 weeks without an increasing 
      hypoglycemic effect, and the add-on therapy with sitagliptin was effective 
      irrespective of the insulin regimen.
FAU - Katsuno, Tomoyuki
AU  - Katsuno T
AD  - Division of Innovative Diabetes Treatment, Hyogo College of Medicine, 1-1 
      Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. katsunoa@hyo-med.ac.jp.
FAU - Ikeda, Hiroki
AU  - Ikeda H
AD  - Ikeda Hospital, 1-18-5 Tsukaguchi-cho, Amagasaki, Hyogo, 661-0002, Japan.
FAU - Namba, Mitsuyoshi
AU  - Namba M
AD  - Division of Diabetes, Endocrinology and Metabolism, Department of Internal 
      Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 
      663-8501, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160425
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC4900980
OTO - NOTNLM
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - Hemoglobin A1c
OT  - Insulin therapy
OT  - Type 2 diabetes mellitus
EDAT- 2016/04/27 06:00
MHDA- 2016/04/27 06:01
PMCR- 2016/04/25
CRDT- 2016/04/27 06:00
PHST- 2016/02/23 00:00 [received]
PHST- 2016/04/27 06:00 [entrez]
PHST- 2016/04/27 06:00 [pubmed]
PHST- 2016/04/27 06:01 [medline]
PHST- 2016/04/25 00:00 [pmc-release]
AID - 10.1007/s13300-016-0170-2 [pii]
AID - 170 [pii]
AID - 10.1007/s13300-016-0170-2 [doi]
PST - ppublish
SO  - Diabetes Ther. 2016 Jun;7(2):309-20. doi: 10.1007/s13300-016-0170-2. Epub 2016 
      Apr 25.